

---

# Guidance for Industry

## Specification of the Unique Facility Identifier (UFI) System for Drug Establishment Registration

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)  
Center for Biological Evaluation and Research (CBER)  
Center for Veterinary Medicine (CVM)  
Office of Regulatory Affairs (ORA)**

**[Date]**

---

**[Procedural]**

# Guidance for Industry

## Specification of the Unique Facility Identifier (UFI) System for Drug Establishment Registration

*Additional copies are available from:*

*Office of Communications  
Division of Drug Information, WO51, Room 2201  
Center for Drug Evaluation and Research  
Food and Drug Administration  
10903 New Hampshire Ave., Silver Spring, MD 20993  
Phone: 301-796-3400; Fax: 301-847-8714  
druginfo@fda.hhs.gov*

*<http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>  
and/or*

*Office of Communication, Outreach and Development, HFM-40  
Center for Biologics Evaluation and Research  
Food and Drug Administration  
1401 Rockville Pike, Rockville, MD 20852-1448*

*<http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>  
(Tel) 800-835-4709 or 301-827-1800  
and/or*

*Communications Staff, HFV-12  
Center for Veterinary Medicine  
Food and Drug Administration  
7519 Standish Place, Rockville, MD 20855  
(Tel) 240-276-9300*

*<http://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/default.htm>*

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)  
Center for Biological Evaluation and Research (CBER)  
Center for Veterinary Medicine (CVM)  
Office of Regulatory Affairs (ORA)**

**[Date]**

**[Procedural]**

**TABLE OF CONTENTS**

|             |  |          |
|-------------|--|----------|
| <b>I.</b>   | <b>INTRODUCTION.....</b>   | <b>1</b> |
| <b>II.</b>  | <b>BACKGROUND.....</b>   | <b>1</b> |
| <b>A.</b>   | <b>Food and Drug Administration Safety and Innovation Act.....</b> | <b>1</b> |
| <b>B.</b>   | <b>Scope of This Guidance.....</b>                                 | <b>1</b> |
| <b>III.</b> | <b>SPECIFICATION OF THE UFI SYSTEM.....</b>                        | <b>2</b> |

## **Guidance for Industry<sup>1</sup>**

# **Specification of the Unique Facility Identifier (UFI) System for Drug Establishment Registration**

This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

## **I. INTRODUCTION**

This guidance specifies the unique facility identifier (UFI) system for registration of domestic and foreign drug establishments. This guidance is intended to address provisions set forth in section 510 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360), as amended by the Food and Drug Administration Safety and Innovation Act (FDASIA) (Public Law 112-144), regarding the specification of the UFI system.

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

## **II. BACKGROUND**

### **A. Food and Drug Administration Safety and Innovation Act**

In July 2012, FDASIA was signed into law. Sections 701 and 702 of FDASIA direct the Secretary to specify the UFI system for registration of domestic and foreign drug establishments. Once the UFI system is specified, section 510 of the FD&C Act, as amended, requires that each initial and annual drug establishment registration include a UFI (21 U.S.C. 360(b), (c), and (i)).

### **B. Scope of This Guidance**

This guidance is intended solely to address the provisions in sections 701 and 702 of FDASIA that direct the Secretary to specify the UFI system for registration of domestic and foreign drug establishments. This guidance reflects current thinking in light of data standards, information

---

<sup>1</sup> This guidance has been prepared by the Office of Compliance in the Center for Drug Evaluation and Research (CDER) in cooperation with CBER, CVM, and ORA at the Food and Drug Administration.

## ***Contains Nonbinding Recommendations***

technology, and information management resources. As these variables change over time, the FDA may revisit this guidance and the specification made in section III of this guidance.

### **III. SPECIFICATION OF THE UFI SYSTEM**

For drug establishment registration, FDA is specifying the following UFI System. At this time, FDA's preferred UFI for a drug establishment is the Data Universal Numbering System D-U-N-S (DUNS) number, assigned and managed by Dun and Bradstreet. The FDA has been using the DUNS number as a registration number for drug establishments since the implementation of electronic drug registration and listing (for information on the electronic submission of registration and listing data, see

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm> ).

Currently, the FDA finds the DUNS number appropriate to meet Agency needs for a data standard for drug establishment registration UFI. The DUNS number is available free of charge to all drug establishments, and further information is available on the FDA Web site at

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162544.htm>. If you want to use an alternative identifier for your drug establishment, contact FDA via email at [eDRLS@fda.hhs.gov](mailto:eDRLS@fda.hhs.gov) .